keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab glioblastoma

keyword
https://www.readbyqxmd.com/read/28527008/the-role-of-bevacizumab-in-the-treatment-of-glioblastoma
#1
REVIEW
Roberto Jose Diaz, Sheikh Ali, Mehreen Gull Qadir, Macarena I De La Fuente, Michael E Ivan, Ricardo J Komotar
Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited studies on health related quality of life and effects on steroid requirements was also undertaken...
May 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28516072/bevacizumab-in-recurrent-glioma-patterns-of-treatment-failure-and-implications
#2
REVIEW
Yi Li, Saad Ali, Jennifer Clarke, Soonmee Cha
Glioblastoma, the most common primary malignant brain tumor in adults, is highly aggressive and associated with a poor prognosis. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor receptor, has increasingly been used in the treatment of recurrent glioblastoma. It has achieved excellent rates of radiographic response, but most patients will progress after only a few months. Upon recurrence, tumors may not enhance, secondary to vascular normalization. We describe four patterns of radiographic progression commonly associated with Bevacizumab failure: 1) Distant enhancing tumor, 2) Local tumor progression without enhancement, 3) Diffuse gliomatosis-like infiltration, and 4) Local or multifocal progression, with enhancement...
April 2017: Brain Tumor Research and Treatment
https://www.readbyqxmd.com/read/28514722/the-interventional-effect-of-new-drugs-combined-with-the-stupp-protocol-on-glioblastoma-a-network-meta-analysis
#3
Mei Li, Xiangqi Song, Jun Zhu, Aijun Fu, Jianmin Li, Tong Chen
OBJECTIVE: New therapeutic agents in combination with the standard Stupp protocol (a protocol about the temozolomide combined with radiotherapy treatment with glioblastoma was research by Stupp R in 2005) were assessed to evaluate whether they were superior to the Stupp protocol alone, to determine the optimum treatment regimen for patients with newly diagnosed glioblastoma. PATIENTS AND METHODS: We implemented a search strategy to identify studies in the following databases: PubMed, Cochrane Library, EMBASE, CNKI, CBM, Wanfang, and VIP, and assessed the quality of extracted data from the trials included...
May 11, 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/28500559/nivolumab-for-patients-with-recurrent-glioblastoma-progressing-on-bevacizumab-a-retrospective-case-series
#4
Marc C Chamberlain, Bryan T Kim
A single institution retrospective evaluation of nivolumab following disease progression on bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS). There is no accepted therapy for recurrent GBM after failure of bevacizumab. 16 adults, ages 52-72 years (median 62), with recurrent GBM were treated. All patients had previously been treated with surgery, concurrent radiotherapy and temozolomide, and post-radiotherapy temozolomide. Bevacizumab (with or without lomustine) was administered to all patients at first recurrence...
May 12, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28499022/quantitative-imaging-biomarkers-for-risk-stratification-of-patients-with-recurrent-glioblastoma-treated-with-bevacizumab
#5
Patrick Grossmann, Vivek Narayan, Ken Chang, Rifaquat Rahman, Lauren Abrey, David A Reardon, Lawrence H Schwartz, Patrick Y Wen, Brian M Alexander, Raymond Huang, Hugo J W L Aerts
Background: Antiangiogenic therapy with bevacizumab is the most widely used treatment option for recurrent glioblastoma, but therapeutic response varies substantially and effective biomarkers for patient selection are not available. To this end, we determine whether novel quantitative radiomic strategies on the basis of magnetic-resonance-imaging (MRI) have the potential to noninvasively stratify survival and progression in this patient population. Methods: In an initial cohort of 126 patients, we identified a distinct set of features representative of the radiographic phenotype on baseline (pre-treatment) MRI...
May 11, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28485350/a-case-series-of-salvage-ccnu-in-high-grade-glioma-who-have-previously-received-temozolomide-from-a-tertiary-care-institute-in-mumbai
#6
V M Patil, R Abhinav, R Tonse, S Epari, T Gupta, R Jalali
INTRODUCTION: In our center, we routinely use CCNU (Lomustine) as salvage treatment in high-grade glioma patients who cannot afford bevacizumab. This exploratory analysis was done to report the efficacy and toxicity associated with this regimen. METHODS: Patients who were treated with salvage CCNU (postexposure to temozolomide) between January 2015 and August 2016 were included for this retrospective analysis. SPSS version 16 was used for this analysis. Time-to-event analysis was performed using the Kaplan-Meier method...
October 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28472567/long-term-benefit-of-intra-arterial-bevacizumab-for-recurrent-glioblastoma
#7
Rachel A Alter, Timothy G White, Andrew A Fanous, Shamik Chakraborty, Christopher G Filippi, David J Pisapia, Apostolos John Tsiouris, John A Boockvar
Standard treatment for recurrent GBM is not yet established. We present a case demonstrating the benefit of intra-arterial (IA) bevacizumab with blood brain barrier disruption (BBBD) for the treatment of recurrent GBM. A 31 year-old man diagnosed with GBM, following primary resection, received temozolomide. After a second resection, he received one dose of IA bevacizumab with BBBD using mannitol, preventing regrowth for 2.5 years. Following tumor regrowth, the patient received another dose of IA bevacizumab with BBBD, which has prevented regrowth for another year...
May 2017: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/28467795/survival-benefit-of-glioblastoma-patients-after-fda-approval-of-temozolomide-concomitant-with-radiation-and-bevacizumab-a-population-based-study
#8
Ping Zhu, Xianglin L Du, Guangrong Lu, Jay-Jiguang Zhu
Few population-based analyses have investigated survival change in glioblastoma multiforme (GBM) patients treated with concomitant radiotherapy-temozolomide (RT-TMZ) and adjuvant temozolomide (TMZ) and then bevacizumab (BEV) after Food and Drug Administration (FDA) approval, respectively. We aimed to explore the effects on survival with RT-TMZ, adjuvant TMZ and BEV in general GBM population based on the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases. A total of 28933 GBM patients from SEER (N = 24578) and TCR (N = 4355) between January 2000 and December 2013 were included...
April 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28446727/bevacizumab-combined-with-chemotherapy-for-glioblastoma-a-meta-analysis-of-randomized-controlled-trials
#9
Shou-Bo Yang, Kai-Di Gao, Tao Jiang, Shu-Jun Cheng, Wen-Bin Li
Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. We analyzed four clinical trials, including 607 patients, to investigate the efficacy and safety of bevacizumab when combined with chemotherapy for the treatment of glioblastomas. Results demonstrated that bevacizumab when combined with chemotherapy improved progression-free survival (HR = 0.66; 95% CI 0.56-0.78; p < 0.00001) compared with bevacizumab or chemotherapy alone...
April 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28438066/angiogenesis-inhibitors-in-tackling-recurrent-glioblastoma
#10
Thomas Hundsberger, David A Reardon, Patrick Y Wen
Despite aggressive multimodality treatment of glioblastoma, outcome remains poor and patients mostly die of local recurrences. Besides reoperation and occasionally reirradiation, systemic treatment of recurrent glioblastoma consists of alkylating chemotherapy (lomustine, temozolomide), bevacizumab and combinations thereof. Unfortunately, antiangiogenic agents failed to improve survival either as a monotherapy or in combination treatments. This review provides current insights into tumor-derived escape mechanisms and other areas of treatment failure of antiangiogenic agents in glioblastoma...
May 2, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28430038/prognostic-implications-of-the-subcellular-localization-of-survivin-in-glioblastomas-treated-with-radiotherapy-plus-concomitant-and-adjuvant-temozolomide
#11
Taiichi Saito, Kazuhiko Sugiyama, Yukio Takeshima, Vishwa Jeet Amatya, Fumiyuki Yamasaki, Takeshi Takayasu, Ryo Nosaka, Yoshihiro Muragaki, Takakazu Kawamata, Kaoru Kurisu
OBJECTIVE Currently, the standard treatment protocol for patients with newly diagnosed glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ). Various prognostic biomarkers for GBM have been described, including survivin expression. The aim of this study was to determine whether the subcellular localization of survivin correlates with GBM prognosis in patients who received the standard treatment protocol. METHODS The authors retrospectively examined the subcellular localization of survivin (nuclear, cytoplasmic, or both) using immunohistochemistry in 50 patients with GBM who had received the standard treatment...
April 21, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28429093/a-case-of-glioblastoma-resected-immediately-after-administering-bevacizumab-consideration-on-histopathological-findings-and-safety-of-surgery
#12
Yukina Tokuda, Ryota Tamura, Kentaro Ohara, Kazunari Yoshida, Hikaru Sasaki
Surgery after administering bevacizumab should be carefully considered particularly because of wound healing concerns. A 27-year-old man presented with multiple tumor recurrences after gross total removal of a left temporal oligodendroglioma (1p/19q-noncodeleted). Whole brain radiotherapy with concomitant temozolomide and bevacizumab was immediately prescribed; however, the patient's condition deteriorated because of brain herniation. Three days after administering bevacizumab, an emergency tumor removal with external decompression and a ventriculo-peritoneal shunt was performed...
April 2017: Brain Tumor Pathology
https://www.readbyqxmd.com/read/28427164/early-tumour-shrinkage-as-a-survival-predictor-in-patients-with-recurrent-glioblastoma-treated-with-bevacizumab-in-the-avareg-randomized-phase-ii-study
#13
Alba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, Michele Reni, Alessandra Fabi, Claudia Caserta, Alicia Tosoni, Marica Eoli, Giuseppe Lombardi, Matteo Clavarezza, Alexandro Paccapelo, Stefania Bartolini, Luigi Cirillo, Raffaele Agati, Enrico Franceschi
BACKGROUND: Disease assessment for recurrent glioblastoma (GBM) represents a challenge, especially with the use of antiangiogenic agents. Moreover, validated neuroradiological predictors of outcome are lacking. Recently, the concept of early tumor shrinkage (ETS) has been developed to better assess the ability of treatments in determining a rapid and remarkable tumor response.The aim of the study was to evaluate the role of ETS in predicting survival of GBM patients treated with BEVMETHODS: We examined the radiological data of patients with recurrent GBM treated with bevacizumab (BEV) or fotemustine (FTM) in the randomized phase II AVAREG trial (EudraCT: 2011-001363-46)...
February 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28420326/transcriptional-changes-induced-by-bevacizumab-combination-therapy-in-responding-and-non-responding-recurrent-glioblastoma-patients
#14
Thomas Urup, Line Mærsk Staunstrup, Signe Regner Michaelsen, Kristoffer Vitting-Seerup, Marc Bennedbæk, Anders Toft, Lars Rønn Olsen, Lars Jønson, Shohreh Issazadeh-Navikas, Helle Broholm, Petra Hamerlik, Hans Skovgaard Poulsen, Ulrik Lassen
BACKGROUND: Bevacizumab combined with chemotherapy produces clinical durable response in 25-30% of recurrent glioblastoma patients. This group of patients has shown improved survival and quality of life. The aim of this study was to investigate changes in gene expression associated with response and resistance to bevacizumab combination therapy. METHODS: Recurrent glioblastoma patients who had biomarker-accessible tumor tissue surgically removed both before bevacizumab treatment and at time of progression were included...
April 18, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28419967/olea-europaea-leaf-extract-and-bevacizumab-synergistically-exhibit-beneficial-efficacy-upon-human-glioblastoma-cancer-stem-cells-through-reducing-angiogenesis-and-invasion-in-vitro
#15
Gulcin Tezcan, Mevlut Ozgur Taskapilioglu, Berrin Tunca, Ahmet Bekar, Hilal Demirci, Hasan Kocaeli, Secil Ak Aksoy, Unal Egeli, Gulsah Cecener, Sahsine Tolunay
Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p=0.0001, p<0.001, p=0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9...
June 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28399638/tumor-treating-fields-plus-chemotherapy-versus-chemotherapy-alone-for-glioblastoma-at-first-recurrence-a-post-hoc-analysis-of-the-ef-14-trial
#16
Santosh Kesari, Zvi Ram
BACKGROUND: This post hoc analysis of the EF-14 trial (NCT00916409) of tumor-treating fields (TTFields) plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma compared the efficacy of TTFields plus chemotherapy (physician's choice) versus chemotherapy alone after first recurrence. METHODS: Patients on TTFields plus temozolomide continued TTFields plus second-line chemotherapy after first recurrence. Some patients on temozolomide alone crossed over after approval of TTFields for recurrent GBM...
April 12, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28386777/bevacizumab-for-malignant-gliomas-current-indications-mechanisms-of-action-and-resistance-and-markers-of-response
#17
Ryota Tamura, Toshihide Tanaka, Keisuke Miyake, Kazunari Yoshida, Hikaru Sasaki
Vascular endothelial growth factor (VEGF) is an attractive target of antiangiogenic therapy in glioblastomas. Bevacizumab (Bev), a humanized anti-VEGF antibody, is associated with the improvement of progression-free survival and performance status in patients with glioblastoma. However, randomized trials uniformly suggest that these favorable clinical effects of Bev do not translate into an overall survival benefit. The mechanisms of action of Bev appear to include the inhibition of tumor angiogenesis, as well as indirect effects such as the depletion of niches for glioma stem cells and stimulation of antitumor immunity...
April 2017: Brain Tumor Pathology
https://www.readbyqxmd.com/read/28373454/a-retrospective-evaluation-of-bevacizumab-treatment-in-patients-with-progressive-malignant-glioma-in-northern-sweden
#18
Maria Sandström, Maria Laudius, Thomas Lindqvist, Thomas Asklund, Mikael Johansson
BACKGROUND/AIM: Overall survival for glioblastoma patients is short. Standard treatment is surgery followed by radiochemotherapy and adjuvant temozolomide. The aim of this study was to evaluate the outcome for all patients with progressive disease treated with bevacizumab-based treatment combinations in the northern region of Sweden. PATIENTS AND METHODS: This was a single-center retrospective analysis after bevacizumab-based second-line treatment for malignant glioma...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28353668/bevacizumab-for-patients-with-recurrent-gliomas-presenting-with-a-gliomatosis-cerebri-growth-pattern
#19
Michael C Burger, Iris C Mildenberger, Marlies Wagner, Michel Mittelbronn, Joachim P Steinbach, Oliver Bähr
Bevacizumab has been shown to improve progression-free survival and neurologic function, but failed to improve overall survival in newly diagnosed glioblastoma and at first recurrence. Nonetheless, bevacizumab is widely used in patients with recurrent glioma. However, its use in patients with gliomas showing a gliomatosis cerebri growth pattern is contentious. Due to the marked diffuse and infiltrative growth with less angiogenic tumor growth, it may appear questionable whether bevacizumab can have a therapeutic effect in those patients...
March 29, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28343250/apparent-diffusion-coefficient-changes-predict-survival-after-intra-arterial-bevacizumab-treatment-in-recurrent-glioblastoma
#20
Naveen Galla, Gloria Chiang, Shamik Chakraborty, Ranjodh Singh, A John Tsiouris, John Boockvar, Ilhami Kovanlikaya
PURPOSE: Superselective intra-arterial cerebral infusion (SIACI) of bevacizumab (BV) has emerged as a novel therapy in the treatment of recurrent glioblastoma (GB). This study assessed the use of apparent diffusion coefficient (ADC) in predicting length of survival after SIACI BV and overall survival in patients with recurrent GB. METHODS: Sixty-five patients from a cohort enrolled in a phase I/II trial of SIACI BV for treatment of recurrent GB were retrospectively included in this analysis...
March 25, 2017: Neuroradiology
keyword
keyword
80321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"